Complementing these findings, Tacke et al. established the clinical relevance of CCL11 as a plasma biomarker, demonstrating that elevated levels correlate with hepatic inflammation severity, advanced fibrosis stages, and poor prognosis in liver cirrhosis patients. The gene discussed is CCL11; the disease is cirrhosis of liver.